TrialJapanese journal of clinical oncology2018

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study.

Ken Ohmachi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.